An Open-Label Two-Stage Trial of the Safety, Pharmacodynamics, Biodistribution, Immunogenicity and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A
Latest Information Update: 04 Jan 2024
At a glance
- Drugs ANB 010 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Acronyms EDELWEISS
- Sponsors Biocad
- 04 Jan 2024 New trial record